Sector News

Becton Dickinson to buy CareFusion for $12bn

October 8, 2014
Life sciences

Medical devices giant Becton Dickinson (BD) has agreed to buy automation and infection prevention specialist CareFusion for over $12 billion (£7.5 billion) in a mixture of shares and borrowed cash.

CareFusion develops technology for reducing drug dispensing errors by automation, and for preventing and detecting infections.

BD says that Carefusion’s products are complementary to its own ranges, and its distribution infrastructure will allow the merged company to increase global sales and cut supply chain costs.

The move follows other consolidation between major players in the medical devices segment, including Medtronic’s $43 billion purchase of Covidien in June.

Source: Chemistry World

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach